PE-Cy7 Anti-Human CD19 (HIB19) Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| FC |
---|---|
Isotype | Mouse IgG1, kappa |
Concentration | 5 uL (0.25 ug)/test |
Reactivity | Human |
Formulation | 10 mM NaH2PO4, 150 mM NaCl, 0.09% NaN3, 0.1% gelatin, pH7.2 |
Host | Mouse |
Gene ID | 930 |
---|---|
Gene Name | CD19 |
Alternative Name(s) | Leu-12, B4 |
Format | PE-Cy7 |
Preparation | This monoclonal antibody was purified from tissue culture supernatant via affinity chromatography. The purified antibody was conjugated under optimal conditions, with unreacted dye removed from the preparation. It is recommended to store the product undiluted at 4°C, and protected from prolonged exposure to light. Do not freeze. |
Application Notes | This antibody preparation has been pre-titrated and quality-tested for flow cytometry using an appropriate cell type. The antibody has been diluted for use at 5 uL per test, defined as the amount of antibody that will stain a cell sample in a final volume of approximately 100 uL. The number of cells within a sample should be determined empirically, but typically ranges between 1x10e5 to 1x10e8 cells. |
Storage Conditions | 2-8°C protected from light |
Kroenke MA, Eto D, Locci M, Cho M, Davidson T, Haddad EK, and Crotty S. 2012. J. Immunol. 188: 3734-3744. (Flow cytometry)
So NSY, Ostrowski MA, and Gray-Owen SD. 2012. J. Immunol. 188: 4008-4022. (in vitro cell capture for microscopy)
Zhang L, Yang N, Conejo-Garcia J-R, Katsaros D, Mohamed-Hadley A, Fracchioli S, Schlienger K, Toll A, Levine B, Rubin SC, and Coukos G. 2003. Clin. Cancer Res. 9: 264 – 272. (Immunohistochemistry)
Hibe W, Dirnhofer S, Oberwasserlechner F, Eisterer W, Amman K, Schmid T, Hilbe G, Thaler J, and Woll E. 2003. J. Clin. Pathol. 56: 736-741. (Immunohistochemistry – frozen tissues)
Provided below are standard protocols that you may find useful for product applications.
Background
The HIB19 antibody reacts with human CD19, 95 kDa glycoprotein which acts as a co-receptor, along with CD21, CD81 and CD225, in support of the functional B cell receptor (BCR). This complex provides antigen-specific recognition and subsequent activation of B cells to proliferate and differentiate into antibody-secreting cells (plasma cells) or memory B cells, which are crucial for secondary antigen encounter. CD19 is a lineage-differentiation marker, as its expression is detectable at the earliest B cell stages, through development, and is finally lost upon transition to mature plasma cells.
The HIB19 antibody is widely used as a phenotypic marker for CD19 expression on B cells, as well as on dendritic cell subsets.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.